Discover
INBX
Inhibrx Biosciences, Inc.
94.94
2 x 74.16
2 x 119.61
bid
ask
+
0.19
0.20%
2 @ 04:00 AM
94.94 +0.00 (0.00%)
| Ytd | 20.18% | |
| 1y | 547.17% |
92.50
day range
103.79
14.95
52 week range
155.29
| Open | 94.00 | Prev Close | 94.75 | Low | 92.50 | High | 103.79 | Mkt Cap | 1.39B |
| Vol | 296.67K | Avg Vol | 450.54K | EPS | -8.39 | P/E | N/A | Forward P/E | -15.04 |
| Beta | 3.32 | Short Ratio | 9.81 | Inst. Own | 83.07% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 106.69 | 200-d Avg | 77.72 | 1yr Est | 277.50 |
| Income Statement | |||
| Operating Expenses | 30.93M | ||
| Research and Development Expense | 25.22M | ||
| Selling, General and Administrative Expense | 5.71M | ||
| Operating Income | -30.93M | ||
| Interest Expense | 3.51M | ||
| Net Income | -33.44M | ||
| Net Income Common Stock | -33.44M | ||
| Net Income Common Stock (USD) | -33.44M | ||
| Consolidated Income | -33.44M | ||
| Earnings per Basic Share | -2.15 | ||
| Earnings per Basic Share (USD) | -2.15 | ||
| Earnings per Diluted Share | -2.15 | ||
| Earning Before Interest & Taxes (EBIT) | -29.93M | ||
| Earning Before Interest & Taxes (USD) | -29.93M | ||
| Weighted Average Shares | 15.59M | ||
| Weighted Average Shares Diluted | 15.59M | ||
| Balance Sheet | |||
| Cash and Equivalents | 161.66M | ||
| Cash and Equivalents (USD) | 161.66M | ||
| Trade and Non-Trade Receivables | 186.00K | ||
| Current Assets | 171.34M | ||
| Property, Plant & Equipment Net | 8.25M | ||
| Total Assets | 183.97M | ||
| Debt Current | 2.41M | ||
| Total Debt | 180.90M | ||
| Current Liabilities | 26.51M | ||
| Debt Non-Current | 178.49M | ||
| Total Liabilities | 205.00M | ||
| Accumulated Retained Earnings (Deficit) | -279.63M | ||
| Shareholders Equity | -21.03M | ||
| Shareholders Equity (USD) | -21.03M | ||
| Assets Non-Current | 12.63M | ||
| Total Debt (USD) | 180.90M | ||
| Liabilities Non-Current | 178.49M | ||
| Trade and Non-Trade Payables | 8.76M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.02M | ||
| Net Cash Flow from Financing | 75.46M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 37.44M | ||
| Issuance (Purchase) of Equity Shares | 471.00K | ||
| Issuance (Repayment) of Debt Securities | 74.99M | ||
| Net Cash Flow from Operations | -38.03M | ||
| Share Based Compensation | 2.65M | ||